Scholarlink

Background <p>Gliomas, particularly astrocytomas (IDH-mutated, 1p/19q intact) and oligodendrogliomas (IDH-mutated, 1p/19q co-deleted), differ significantly in their clinical behavior and prognosis. Accurate differentiation between these subtypes is crucial for guiding therapeutic decisions. Non-invasive imaging biomarkers, such as T2-Flair mismatch sign and relative cerebral blood volume (rCBV), have shown promise in glioma classification.</p> Methods <p>This retrospective multicenter study analyzed 42&#xa0;patients with astrocytoma and 21&#xa0;with oligodendroglioma. Demographic, histopathological, and imaging data were collected, with a&#xa0;focus on rCBV parameters derived from dynamic susceptibility contrast perfusion MRI. Statistical analyses were conducted to assess differences between the groups and evaluate the discriminatory power of rCBV metrics. After correction for multiple corrections, level of significance was set at <i>p</i> &lt; 0.01.</p> Results <p>Patients with astrocytoma and oligodendroglioma were similar in age and gender distribution (mean age and male-female-ratio; <i>p</i> = 0.01 respectively <i>p</i> = 0.04). The rCBVmax value was significantly higher in oligodendrogliomas (11.64 vs. 7.69, <i>p</i> &lt; 0.001) and demonstrated a&#xa0;good discriminatory power (AUC = 0.764). Median and mean rCBV values showed non-significant differences between oligodendroglioma and astrocytoma (<i>p</i> = 0.02 respectively <i>p</i> = 0.03).</p> Conclusion <p>rCBVmax emerges as a&#xa0;potential imaging marker for differentiating oligodendrogliomas from astrocytomas. These findings can be explained by biological properties of oligodendrogliomas and thereby underscore the potential of advanced imaging techniques in non-invasive glioma classification. However, larger prospective studies are required to validate these results and standardize imaging protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月18日

查看全文
  • Manoj Mannil,
  • Christian Rubbert,
  • Manfred Musigmann,
  • Mathias Prokop,
  • Paola Feraco,
  • Frederick J. A. Meijer,
  • Marion Smits,
  • Anja G. Van der Kolk,
  • Dylan Henssen

摘要

Background

Gliomas, particularly astrocytomas (IDH-mutated, 1p/19q intact) and oligodendrogliomas (IDH-mutated, 1p/19q co-deleted), differ significantly in their clinical behavior and prognosis. Accurate differentiation between these subtypes is crucial for guiding therapeutic decisions. Non-invasive imaging biomarkers, such as T2-Flair mismatch sign and relative cerebral blood volume (rCBV), have shown promise in glioma classification.

Methods

This retrospective multicenter study analyzed 42 patients with astrocytoma and 21 with oligodendroglioma. Demographic, histopathological, and imaging data were collected, with a focus on rCBV parameters derived from dynamic susceptibility contrast perfusion MRI. Statistical analyses were conducted to assess differences between the groups and evaluate the discriminatory power of rCBV metrics. After correction for multiple corrections, level of significance was set at p < 0.01.

Results

Patients with astrocytoma and oligodendroglioma were similar in age and gender distribution (mean age and male-female-ratio; p = 0.01 respectively p = 0.04). The rCBVmax value was significantly higher in oligodendrogliomas (11.64 vs. 7.69, p < 0.001) and demonstrated a good discriminatory power (AUC = 0.764). Median and mean rCBV values showed non-significant differences between oligodendroglioma and astrocytoma (p = 0.02 respectively p = 0.03).

Conclusion

rCBVmax emerges as a potential imaging marker for differentiating oligodendrogliomas from astrocytomas. These findings can be explained by biological properties of oligodendrogliomas and thereby underscore the potential of advanced imaging techniques in non-invasive glioma classification. However, larger prospective studies are required to validate these results and standardize imaging protocols.